
Optinose Reports $22.4 Million in Preliminary Q4 Revenue for XHANCE
YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth quarter of 2024, driven by sustained growth in prescriptions for XHANCE® (fluticasone …
Optinose Reports $22.4 Million in Preliminary Q4 Revenue for XHANCE Read More